AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16214284 — intervention group
Group type: COMPARATOR
Intervention: One‐Step with self‐etch technique
Number of subjects: 20
Study 15238368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalist model of care
Number of subjects: 526
Study 15238368 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 526
Study 11339980 — intervention group
Group type: EXPERIMENTAL
Intervention: SAS macro for sample size re-estimation using EM algorithm
Number of subjects: 0
Study 9246699 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole once daily
Number of subjects: 495
Study 9246699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 8334339 — intervention group
Group type: EXPERIMENTAL
Intervention: Baoshen Pill (Rheum palmatum extract, RPE)
Number of subjects: 42
Study 8334339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 6430311 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 80
Study 6430311 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 80
Study 6430311 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 80
Study 6430311 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 80
Study 30530959 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT) - Upper trunk group (UTG)
Number of subjects: 35
Study 30530959 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT) - Global trunk group (GTG)
Number of subjects: 35
Study 30530959 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT) - Both groups
Number of subjects: 35
Study 30129815 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 grams/day of freeze-dried grape powder (GRAPE)
Number of subjects: 20
Study 30129815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26677207 — intervention group
Group type: EXPERIMENTAL
Intervention: PA resource kit consisting of tailored print materials and a step pedometer
Number of subjects: 95
Study 26677207 — intervention group
Group type: COMPARATOR
Intervention: Standard public health PA recommendation
Number of subjects: 95
Study 24022919 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobic training (n = 19)
Number of subjects: 52
Study 24022919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry land aerobic training (n = 19)
Number of subjects: 52
Study 24022919 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group (n = 14)
Number of subjects: 52
Study 23035867 — intervention group
Group type: EXPERIMENTAL
Intervention: High post-randomization mean IOP level and/or large variability in IOP
Number of subjects: 0
Study 23035867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors including treatment assignment, baseline IOP, gender, race, and history of hypertension
Number of subjects: 0
Study 23035867 — intervention group
Group type: EXPERIMENTAL
Intervention: Different patterns of IOP change identified in EGPS
Number of subjects: 0
Study 20588018 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (ischemic postconditioning with short repetitive cycles of reperfusion and re-occlusion)
Number of subjects: 260
Study 20588018 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 260
Study 17446206 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg atomoxetine
Number of subjects: 60
Study 17446206 — intervention group
Group type: COMPARATOR
Intervention: 30 mg citalopram
Number of subjects: 60
Study 17446206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16463414 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Water Running (DWR)
Number of subjects: 60
Study 16463414 — intervention group
Group type: COMPARATOR
Intervention: Land-Based Exercises (LBE)
Number of subjects: 60
Study 15645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-phase fluoride dentifrice containing sodium bicarbonate, calcium, and phosphate
Number of subjects: 87
Study 15645907 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride dentifrice (control)
Number of subjects: 87
Study 10758456 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal cranial needle approach for brachial plexus blockade
Number of subjects: 0
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-FU (Group A)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tegafur (Group B)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. MMC + oral 5-FU (Group C)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II (Group A)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II (Group B)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II (Group C)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III (Group A)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III (Group B)
Number of subjects: 874
Study 8751804 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III (Group C)
Number of subjects: 874
Study 1290861 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 21
Study 1290861 — intervention group
Group type: COMPARATOR
Intervention: Control (bolus-fed)
Number of subjects: 21
Study 6691531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient outcome measurement instruments
Number of subjects: 48
Study 30654249 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma selenium concentration
Number of subjects: 266
Study 30654249 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma selenium concentration and high DMA%
Number of subjects: 266
Study 28276001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid-based formula
Number of subjects: 153
Study 28276001 — intervention group
Group type: COMPARATOR
Intervention: Soy-protein-based formula
Number of subjects: 153
Study 28276001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid-based formula and Soy-protein-based formula
Number of subjects: 153
Study 26232831 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual information via YouTube (6-minute video)
Number of subjects: 60
Study 26232831 — intervention group
Group type: COMPARATOR
Intervention: Routine verbal and written patient information
Number of subjects: 60
Study 23914462 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmented podcast lecture
Number of subjects: 35
Study 23914462 — intervention group
Group type: COMPARATOR
Intervention: Unsegmented podcast lecture
Number of subjects: 35
Study 23914462 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face lecture
Number of subjects: 35
Study 22224244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceraxon (2 g daily for 10 days)
Number of subjects: 106
Study 22224244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (10 ml daily for 10 days)
Number of subjects: 106
Study 22224244 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic treatment without neuroprotectors)
Number of subjects: 106
Study 22224244 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 106
Study 18976988 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical decision-making based on hidden state inference
Number of subjects: 0
Study 18976988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of future outcomes
Number of subjects: 0
Study 18976988 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle filter model
Number of subjects: 0
Study 16525816 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sarizotan HCl b.i.d. for 8 days
Number of subjects: 18
Study 16525816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12740037 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 45
Study 12740037 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 45
Study 10740549 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms kg-1
Number of subjects: 61
Study 10740549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms kg-1
Number of subjects: 61
Study 10740549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4 micrograms kg-1
Number of subjects: 61
Study 8737134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose on day 1 followed by 200 mg once daily for pneumonia; 200 mg loading dose on day 1 followed by 100 mg daily for COPD)
Number of subjects: 2081
Study 8737134 — intervention group
Group type: COMPARATOR
Intervention: Comparator regimens (amoxycillin/clavulanic acid 500/125 mg tid, amoxycillin 1000 mg tid, amoxycillin 1000 mg tid plus ofloxacin 200 mg bid, erythromycin 1000 mg bid)
Number of subjects: 2081
Study 1577399 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomoxir 50 mg
Number of subjects: 8
Study 1577399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6374921 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (Chymopapain group 1)
Number of subjects: 52
Study 6374921 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (Chymopapain group 2)
Number of subjects: 52
Study 6374921 — intervention group
Group type: COMPARATOR
Intervention: Surgery (Surgical group)
Number of subjects: 52
Study 6374921 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain (failed Chymopapain group)
Number of subjects: 52
Study 6374921 — intervention group
Group type: COMPARATOR
Intervention: Surgery (failed Chymopapain group)
Number of subjects: 52
Study 30739019 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel/carboplatin (nab-PC)
Number of subjects: 127
Study 30739019 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/carboplatin (GC)
Number of subjects: 127
Study 30051934 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindness intervention
Number of subjects: 144
Study 30051934 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude intervention
Number of subjects: 144
Study 30051934 — intervention group
Group type: COMPARATOR
Intervention: Control condition (treatment as usual)
Number of subjects: 144
Study 27665153 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider's LARC training intervention
Number of subjects: 1500
Study 27665153 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 1500
Study 24522288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 lx of fluorescent lighting environment
Number of subjects: 17
Study 24522288 — intervention group
Group type: COMPARATOR
Intervention: Dark environment
Number of subjects: 17
Study 22314458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bypass methylprednisolone 30mg/kg
Number of subjects: 40
Study 22314458 — intervention group
Group type: COMPARATOR
Intervention: Post-bypass methylprednisolone 30mg/kg
Number of subjects: 40
Study 20561314 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries Management System
Number of subjects: 0
Study 17587394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 222
Study 17587394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 16259890 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 100
Study 16259890 — intervention group
Group type: COMPARATOR
Intervention: Open vertical banded gastroplasty (VBG)
Number of subjects: 100
Study 11792161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment with levetiracetam (500 mg twice daily)
Number of subjects: 10
Study 11792161 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with levetiracetam (individualized, 500-1000 mg twice daily for 8 weeks)
Number of subjects: 10
Study 11792161 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 9504515 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone plus proguanil
Number of subjects: 320
Study 9504515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 8295772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.56 mg/kg/4 min or 0.84 mg/kg over 10 min)
Number of subjects: 41
Study 8295772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (10-20-30-40 micrograms/kg/min over 3 min each step)
Number of subjects: 41
Study 3057962 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant therapy
Number of subjects: 0
Study 3057962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug
Number of subjects: 0
Study 3057962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31231780 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses at months 0 and 6
Number of subjects: 301
Study 31231780 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses at months 0, 1 and 6
Number of subjects: 301
Study 31231780 — intervention group
Group type: COMPARATOR
Intervention: 3 doses in women aged 18-26 years
Number of subjects: 301
Study 31083194 — intervention group
Group type: EXPERIMENTAL
Intervention: 75IU HMG and 75IU rFSH
Number of subjects: 3
Study 31083194 — intervention group
Group type: EXPERIMENTAL
Intervention: 150IU rFSH and 75IU rLH
Number of subjects: 3
Study 31083194 — intervention group
Group type: COMPARATOR
Intervention: 150IU rFSH alone
Number of subjects: 3
Study 28695267 — intervention group
Group type: EXPERIMENTAL
Intervention: AAFP 500 mg with methylprednisolone (4 mg twice daily)
Number of subjects: 37
Study 28695267 — intervention group
Group type: COMPARATOR
Intervention: OAA 1000 mg with prednisone (5 mg twice daily)
Number of subjects: 37
Study 23299569 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening early identification (SS)
Number of subjects: 0
Study 23299569 — intervention group
Group type: COMPARATOR
Intervention: Consultation‐based early identification (CEI)
Number of subjects: 0
Study 21639872 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous E.coli autovaccine
Number of subjects: 9
Study 18419441 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/day)
Number of subjects: 161
Study 18419441 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline alone
Number of subjects: 161
Study 18419441 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus diethylcarbamazine-albendazole
Number of subjects: 161
Study 18419441 — intervention group
Group type: COMPARATOR
Intervention: Placebo doxycycline plus diethylcarbamazine-albendazole
Number of subjects: 161
Study 18419441 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus placebo diethylcarbamazine-albendazole
Number of subjects: 161
Study 16497347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (3-day regimen)
Number of subjects: 62
Study 16497347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (3-day regimen)
Number of subjects: 62
Study 16497347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus Primaquine
Number of subjects: 62
Study 16497347 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine plus Primaquine
Number of subjects: 62
Study 16497347 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine and Quinine
Number of subjects: 62
Study 12831736 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased knee flexion velocity at toe-off to normal levels
Number of subjects: 32
Study 12831736 — intervention group
Group type: COMPARATOR
Intervention: Average knee extension moment from toe-off to peak flexion
Number of subjects: 32
Study 12831736 — intervention group
Group type: COMPARATOR
Intervention: Knee flexion velocity at toe-off
Number of subjects: 32
Study 11122544 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin alone
Number of subjects: 900
Study 11122544 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin plus tirofiban
Number of subjects: 900
Study 11122544 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 900
Study 11122544 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH plus tirofiban
Number of subjects: 900
Study 11122544 — intervention group
Group type: COMPARATOR
Intervention: Placebo for enoxaparin
Number of subjects: 900
Study 11122544 — intervention group
Group type: COMPARATOR
Intervention: Placebo for tirofiban
Number of subjects: 900
Study 9154031 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by trainee doctors with indirect assistance from computerised decision support system
Number of subjects: 148
Study 9154031 — intervention group
Group type: COMPARATOR
Intervention: Management by trainee doctors without assistance from computerised decision support system
Number of subjects: 148
Study 7634283 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment to achieve blood pressure levels below 85 mmHg
Number of subjects: 0
Study 7634283 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2454357 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg, administered orally, single and twice daily regimen
Number of subjects: 0
Study 2454357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2454357 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (control)
Number of subjects: 0
Study 31479417 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-lncRNA signature
Number of subjects: 343
Study 31479417 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional experiments with six out of the eight lncRNAs
Number of subjects: 343
Study 28812398 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercises
Number of subjects: 97
Study 28812398 — intervention group
Group type: COMPARATOR
Intervention: Unspecific exercises
Number of subjects: 97
Study 25792708 — intervention group
Group type: EXPERIMENTAL
Intervention: BET 2×1 mg/day (BET1, n=19)
Number of subjects: 76
Study 25792708 — intervention group
Group type: EXPERIMENTAL
Intervention: BET 2×2 mg/day (BET2, n=19)
Number of subjects: 76
Study 25792708 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS 2×5 mL (0.4 mg/mL)/day (BVS, n=19)
Number of subjects: 76
Study 25792708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=19)
Number of subjects: 76
Study 25792708 — intervention group
Group type: EXPERIMENTAL
Intervention: All budesonide groups (BET1, BET2, BVS)
Number of subjects: 76
Study 25792708 — intervention group
Group type: EXPERIMENTAL
Intervention: BET1
Number of subjects: 76
Study 25792708 — intervention group
Group type: EXPERIMENTAL
Intervention: All budesonide groups
Number of subjects: 76
Study 25792708 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablet
Number of subjects: 76
Study 24411508 — intervention group
Group type: EXPERIMENTAL
Intervention: DMIE intervention (personal navigators, enhanced medical care, and employment supports)
Number of subjects: 2279
Study 20854449 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parenting programme
Number of subjects: 46
Study 20854449 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 46
Study 18818905 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg
Number of subjects: 21
Study 18818905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21
Study 18818905 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 21
Study 17379979 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery (Group A)
Number of subjects: 20
Study 17379979 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery (Group B)
Number of subjects: 20
Study 17379979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 15450781 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated bipolar patients
Number of subjects: 66
Study 15450781 — intervention group
Group type: COMPARATOR
Intervention: Lithium-treated patients
Number of subjects: 66
Study 11931601 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadate CD (methylphenidate HCI, USP) Extended‐Release Capsules sprinkled onto applesauce
Number of subjects: 26
Study 11931601 — intervention group
Group type: COMPARATOR
Intervention: Intact Metadate CD capsules
Number of subjects: 26
Study 9807540 — intervention group
Group type: EXPERIMENTAL
Intervention: Written feedback and financial bonus (intervention group)
Number of subjects: 52
Study 9807540 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 8720348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 250
Study 8720348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 2565841 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine plus placebo
Number of subjects: 12
Study 2565841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine plus famotidine
Number of subjects: 12
Study 2565841 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine alone
Number of subjects: 12
Study 2565841 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 12
Study 3093 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 3093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6102231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 30
Study 6102231 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 30
Study 6102231 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 30
Study 30664512 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Action Observation (FAO) training
Number of subjects: 35
Study 30664512 — intervention group
Group type: COMPARATOR
Intervention: General Action Observation (GAO) training
Number of subjects: 35
Study 28645284 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous individuals living in remote areas
Number of subjects: 535
Study 28645284 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged over 65 years
Number of subjects: 535
Study 28645284 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 535